ALK rearrangement
Showing 1 - 25 of 447
ALK Phosphorylation Trial in Harbin (crizotinib for rearrangement-negative, high phosphorylated ALK patients)
Completed
- ALK Phosphorylation
- crizotinib for rearrangement-negative, high phosphorylated ALK patients
-
Harbin, Heilongjiang, ChinaHarbin Medical University Cancer Hospital
Mar 19, 2023
Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)
Not yet recruiting
- Radiotherapy Side Effect
- +2 more
- SBRT/SRS/radiation therapy
-
Stockholm, SwedenKarolinska University Hospital
Feb 16, 2023
NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)
Not yet recruiting
- NSCLC, Stage III
- ALK-rearrangement
-
Angers, France
- +19 more
Feb 8, 2023
ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)
Recruiting
- ROS1 Rearrangement Non-small Cell Lung Cancer
- ALK Rearrangement Non-small Cell Lung Cancer
-
ShangHai, Shanghai, ChinaShanghai Chest hospital affiliated to Shanghai jiao tong univers
Sep 14, 2021
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Orange, California
- +13 more
Jan 31, 2023
NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)
Available
- Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
-
Stanford, California
- +3 more
Oct 18, 2022
NSCLC Trial in Worldwide (Capmatinib, Spartalizumab, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Capmatinib
- +2 more
-
Fayetteville, Arkansas
- +7 more
Jan 21, 2022
NSCLC (NSCLC) Trial in China (Capmatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
Xiamen, Fujian, China
- +18 more
Jan 27, 2023
NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,
Recruiting
- NSCLC Stage IIIB
- +4 more
- Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
- Carboplatin + Pemetrexed + Atezolizumab
-
Angers, France
- +30 more
Jun 7, 2021
Lung Tumors Trial in France (ALK analysis on CTCs detected by ISET)
Completed
- Lung Neoplasms
- ALK analysis on CTCs detected by ISET
-
Caen, France
- +10 more
Dec 7, 2020
Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)
Recruiting
- Nsclc
- +5 more
- Pembrolizumab
- +3 more
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 25, 2021
NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement Trial in France
Completed
- NSCLC
- +2 more
-
Aix en Provence, France
- +25 more
Sep 24, 2021
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)
Unknown status
- ALK Gene Rearrangement Positive
- Non-Squamous Non-Small Cell Neoplasm of Lung
-
Mexico City, MexicoInstituto Nacional de Cancerologia
Feb 8, 2021
NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)
Recruiting
- Non-small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- RNAseq
-
Saint-Denis, La Réunion, France
- +44 more
Nov 4, 2021
Plasma NGS for Assessment, Characterization, Evaluation of ALK
Active, not recruiting
- Non-Small Cell Lung Cancer
- Plasma Next Generation Sequencing (NGS)
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 26, 2023
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure
Completed
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Sep 23, 2021
Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Tumor-infiltrating Lymphocytes (TIL)
- +5 more
-
Tampa, FloridaMoffitt Cancer Center
Dec 28, 2022
ALK Positive NSCLC Trial in Guangzhou (Loratinib)
Recruiting
- ALK Positive Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial Perople's Hospital
Oct 19, 2023
ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The
Completed
- Non-small Cell Lung Cancer
-
Cairo / Misr Al Qadimah, Egypt
- +10 more
May 14, 2019
First Line Crizotinib for ALK Rearranged Non-squamous Non-small
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 1, 2022
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)
Recruiting
- Non Small Cell Lung Cancer
-
Goyang-si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life
Recruiting
- Cancer
- +15 more
- Data collection and quality of life questionnaire
-
Graz, Austria
- +40 more
Jul 27, 2021